Monday, April 28, 2025

Latest

Yield Growth Corp Continues Push Towards Psychedelic Mushroom Investment Narrative

The Yield Growth Corp (CSE: BOSS) is continuing to push its recently announced psilocybin mushroom narrative. The firm announced today that they have obtain a number of recipes under their new mushroom-focused subsidiary, Flourish Mushroom Labs Inc. The recipes, of which there are nine in total, were acquired for 120,000 shares of Yield Growth at market prices on September 20 – roughly $32,000.

To be clear, the recipes that the firm acquired are for edible, legal mushrooms – types of which include Lion’s Mane, Turkey Tail, Reishi, and Shitake among others. However, Yield Growth is doing acrobatics to connect these edible mushroom recipes to that of the potential psilocybin, or “magic mushroom” market. The formulations are primarily for teas and soups.

These healthy edible mushroom formulations have the potential to be made with psilocybin mushrooms in jurisdictions where magic mushrooms are legal. We are pleased to add mushroom formulas to our extensive catalogue of cannabis formulas which are at various stages of commercialization.

Penny Green, CEO of Yield Growth Corp

The news release itself, while announcing that it had acquired recipes for items such as “chai latte green tea flavor mushroom tea,” “veggie mix for mushroom soup,” and “pumpkin spice mushroom elixir,” was primarily focused on psilocybin mushrooms – a potential new legal sector that some investors are hoping is as big as the “cannabis rush” that occurred over the past few years. The release identified a number of markets where the psychedelic mushrooms are legal, however Yield Growth didn’t indicate that it was actually interested in entering these markets.

It’s unclear when these new products will make it to market.

Yield Growth Corp is currently trading at $0.265 on the Canadian Securities Exchange.


Information for this briefing was found via Sedar and The Yield Growth Corp. The author has no securities or affiliations related to the discussed organizations. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024

Related News

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its...

Tuesday, August 10, 2021, 08:36:06 AM

Yield Growth Corp To Enter Mushroom and Psychoactive Space

The Yield Growth Corp (CSE: BOSS) is newly focused on the mushroom business – both...

Tuesday, September 17, 2019, 01:33:08 PM

Shroom Boom! Has Michael Frank Brought Revive Back from the Dead?

Yesterday Revive Therapeutics (CSE: RVV) increased 81.8% from 5.5c to 10c on 4.1M shares traded....

Thursday, March 5, 2020, 08:46:25 AM

Mind Cure Announces new CTO, Geoff Belair

This morning Mind Cure Health Inc. (CSE: MCUR) announced the hiring of Geoff Belair as...

Thursday, October 15, 2020, 09:39:12 AM

Revive Therapeutics Enters LOI To Acquire Psilocybin Program From PharmaTher

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a letter of...

Monday, December 21, 2020, 08:38:29 AM